Articles tagged "FTY720 immunosuppressant"

2022 American Transplant Congress
Immunosuppressants Alter Lymph Node Architecture and Create Distinct Microbiome Footprints
S. J. Gavzy¹, R. Lakhan², J. Iyyathurai², V. Saxena², L. Li², B. Ma², E. Mongodin², J. S. Bromberg²
¹University of Maryland School of Medicine, Baltimore, MD, ²University of Maryland, Baltimore, MD
*Purpose: There are complex interactions among immunosuppressants, antibiotics, and the gut microbiome on the host immune system. Microbiota can alter lymph node (LN) structure and…
2019 American Transplant Congress
FTY720 Regulates Mitochondria Biogenesis in Dendritic Cells to Prevent Kidney Ischemic Reperfusion Injury
A. Bajwa¹, V. Bontha¹, C. Kuscu¹, L. Gallon², C. Kuscu¹, J. Eason³, D. Maluf¹, V. Mas⁴
¹UTHSC, Memphis, TN, ²Northwestern University, Chicago, IL, ³Director Transplant Institute, Memphis, TN, ⁴Director Transplant Reserach Institute, Memphis, TN
*Purpose: FTY720, a S1PR agonist has been shown to protect kidneys from IRI. However, systemic use is limited due to adverse side effects. Dendritic cells…
2017 American Transplant Congress
CTLA4-Ig in Combination with FTY720 Reduces the Frequency of Memory Alloreactive T Cells and Promotes Heart Allograft Survival in Sensitized Recipients.
S. Khiew,¹ J. Yang,¹ J. Young,¹ J. Chen,¹ Q. Wang,¹ D. Ying,¹ V. Vu,¹ M. Miller,² R. Sciammas,³ M.-L. Alegre,² A. Chong.¹
¹Section of Transplantation, Department of Surgery, University of Chicago, Chicago, IL; ²Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL; ³Center for Comparative Medicine, University of California, Davis, CA
Despite recent evidence of improved graft outcomes and safety, high incidence of early acute cellular rejection with belatacept has limited its use in clinical transplantation.…